/Bio-Techne%20ground%20sign%20outside%20of%20the%20office%20in%20San%20Jose%2C%20California%2C%20USA%20-%20June%208%2C%202023_%20By%20JHVEPhoto.jpeg)
Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at $11.3 billion by market cap, the company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.
Shares of this leading life sciences reagents and instruments company have outperformed the broader market over the past year. TECH has gained 35.1% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.1%. In 2026, TECH stock is up 23.1%, surpassing the SPX’s 13.1% rise on a YTD basis.
